
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

Koji Sasaki,^{1,2} Hagop Kantarjian,¹ Elias Jabbour,¹ Farhad Ravandi,¹ Koichi Takahashi,¹ Marina Konopleva,¹ Gautam Borthakur,¹ Guillermo Garcia-Manero,¹ William Wierda,¹ Naval Daver,¹ Preetesh Jain,¹ Toshihisa Satta,¹ Sherry Pierce,¹ May Beth Rios,¹ and Jorge E. Cortes¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; and ²Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan

*Correspondence: jcortes@mdanderson.org
doi:10.3324/haematol.2015.139089*

Supplemental table 1. Cumulative toxicity after propensity score matching*

Toxicity, No. (%)	IM800 [n=87]		Dasatinib [n=87]		P	IM800 [n=97]		Nilotinib [n=97]		P
	G1/2	G3/4	G1/2	G3/4		G1/2	G3/4	G1/2	G3/4	
Non-hematologic toxicity										
Fatigue	52 (60)	2 (2)	53 (61)	7 (8)	0.184	62 (64)	1 (1)	41 (42)	1 (1)	0.010
Musculoskeletal pain	67 (77)	3 (3)	42 (48)	5 (6)	<0.001	74 (76)	3 (3)	22 (23)	3 (3)	<0.001
Nausea/vomiting	48 (55)	3 (3)	36 (41)	1 (1)	0.082	49 (51)	4 (4)	24 (25)	1 (1)	<0.001
Diarrhea	45 (52)	4 (5)	38 (44)	4 (5)	0.554	50 (52)	3 (3)	11 (11)	0	<0.001
Mucositis/Oral pain	7 (8)	0	24 (28)	0	0.001	6 (6)	0	3 (3)	0	0.306
Skin rash/pruritus	49 (53)	10 (12)	29 (33)	1 (1)	<0.001	55 (57)	8 (8)	55 (57)	1 (1)	0.047
Sensory neuropathy	5 (6)	0	27 (31)	3 (3)	<0.001	5 (5)	0	7 (7)	0	0.551
Anxiety	7 (8)	0	5 (6)	0	0.550	6 (6)	0	2 (2)	0	0.149
Depression	11 (13)	0	7 (8)	0	0.319	13 (13)	0	3 (3)	0	0.009
Memory impairment/Dizziness	16 (18)	0	38 (44)	6 (7)	<0.001	14 (14)	1 (1)	10 (10)	0	0.404
Edema	70 (81)	1 (1)	33 (38)	0	<0.001	76 (78)	3 (3)	5 (5)	0	<0.001
Liver function test	28 (32)	4 (5)	16 (18)	0	0.010	29 (30)	4 (4)	59 (61)	2 (2)	<0.001
Bilirubin	2 (2)	0	1 (1)	0	0.560	2 (2)	0	54 (56)	6 (6)	<0.001
Amylase/Lipase	0	0	0	0	1.000	0	0	3 (3)	4 (4)	0.026
Pleural effusion	0	0	15 (17)	4 (6)	<0.001	0	0	2 (2)	0	0.155
Hematologic toxicity										
Neutropenia	21 (24)	22 (25)	2 (2)	8 (9)	<0.001	32 (33)	23 (24)	5 (5)	3 (3)	<0.001
Anemia	56 (64)	6 (7)	27 (31)	2 (2)	<0.001	63 (65)	10 (10)	11 (11)	1 (1)	<0.001
Thrombocytopenia	18 (21)	17 (20)	10 (12)	10 (12)	0.050	29 (30)	20 (21)	1 (1)	5 (5)	<0.001

* Grading of toxicity spans different versions of CTC/CTCAE from version 2 to version 4